© 2024, Netherlands Foreign Investment Agency, Government of the Netherlands. All Rights Reserved.
Privacy Policy |
Terms of Use
At the conference, Peter Gisberts, Director U-TRIAL (the Utrecht Trial Innovation Alliance) & THINC. Healthcare at UMC Utrecht will present the outcome of the ‘European-benchmark study clinical trial site selection: the Netherlands, Belgium, Denmark, France, Germany and the United Kingdom’
The Netherlands partnered with Citeline to produce an extensive study on the attractiveness of conducting clinical trials in 7 European countries. Join this session to learn more about broad trends and find out in which areas the Netherlands stands out.
The Netherlands is renowned for its expertise in early-stage clinical research but performs equally well in other clinical phases. Around 600 new clinical drug trials are initiated annually, with approximately 60,000 participants. The country especially has a strong oncology trials presence, comprising a third of all initiated trials since 2018.
As Europe’s connected LSH metropolis, the Netherlands provides a clinical research climate with:
Academic excellence
The Netherlands excels in scientific output, researcher quality and academic networks. Top Dutch universities strengthen its position among the top 100 in Europe for clinical and life science research.
Ease-of conducting clinical trials
Easy access to stakeholders facilitated by a broad landscape of research networks makes collaboration easy.
Patient availability
The Netherlands is faster at enrolling trials across a broad range of indications vs. other European countries like France, Germany, the UK, Belgium, Denmark & Spain.
Infrastructure
Close proximity to hospitals and high number of physicians for the population size is an advantage for patients regarding access to trial infrastructure and resource.
The Netherlands offers unique opportunities for the enrolment of clinical trials. The country has a well connected and collaborative clinical research infrastructure with knowledge institutes, science parks and CROs. All 7 University Medical Centers and most hospitals have extensive experience with running clinical trials and offer excellent facilities. And 8 Science parks with high concentrations of innovative companies facilitate clinical research by offering 300+ lab facilities specialized or suitable for clinical research.
The Invest in Holland Life Sciences & Health team will also be attending the conference and is looking forward to discussing how the Netherlands can be a good fit for your company’s clinical research. Meet with our representative Steven Jonis or get in touch for more information.
Register your conference pass here.
New EU Regulation for Clinical Trials with Medicinal Products Applicable on January 31, 2022
Multinational Clinical Research Firm TASK Opens Research Facility in the Netherlands